Breakthrough for Migraine Sufferers: Pfizer’s Zavzpret Nasal Spray Approved by FDA

Pfizer’s Zavzpret nasal spray has been approved by the U.S. Food and Drug Administration (FDA) to quickly relieve the painful symptoms of migraines. The drug, also known as zavegepant, has been approved for the treatment of acute migraines in adults with or without an aura, and it is expected to be launched in July.

Angela Hwang, Pfizer’s Chief Commercial Officer and President of Global Biopharmaceuticals Business, stated, “The FDA approval of Zavzpret marks a significant breakthrough for people with migraine who need freedom from pain and prefer alternative options to oral medications.”

Zavzpret works by blocking the calcitonin gene-related peptide (CGRP) receptor, which is believed to play a role in the development of migraines. By blocking this receptor, the drug reduces the release of CGRP, which can help alleviate the symptoms of migraines.

The FDA’s approval of Zavzpret was based on the results of two Phase 3 clinical trials involving 2,107 patients. In both studies, patients who received the nasal spray experienced significant relief from migraine pain within two hours of taking the medication, compared to those who received a placebo.

Migraines are a common neurological disorder that affects an estimated 39 million Americans. The availability of Zavzpret offers new hope for patients who need quick and effective relief from migraine pain. Pfizer’s development of this drug is a promising step forward in the treatment of migraines and offers hope for those who have struggled to find effective relief from this debilitating condition.